The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients

NCT06639854 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

105

Enrollment

OTHER

Sponsor class

Conditions

Cytomegalovirus Cell Mediated Immunity
Hematopoietic Cell Transplant

Interventions

PROCEDURE: Hematopoietic Cell Transplant
DRUG: Letermovir

Sponsor

M.D. Anderson Cancer Center